Skadden Advises Endo On $1.2B Qualitest Purchase
Endo Pharmaceuticals said Tuesday it has agreed to buy privately held generic drug company Qualitest Pharmaceuticals in a $1.2 billion deal that will expand its offerings in pain management drugs....To view the full article, register now.
Already a subscriber? Click here to view full article